BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd (Chengdu Rongsheng), intends to acquire 100% equity interest in Wuhan Zhongyuan Ruide Biological Products Co., Ltd (Zhongyuan Ruide), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (CSL Asia Pacific), for a total consideration of USD 185 million.
Zhongyuan Ruide, a blood products company, holds 13 marketing approvals for products such as human serum albumin, intravenous human immunoglobulin, and specific human immunoglobulins. Upon completion of the acquisition, Tiantan Biological will gain control of five operating plasma collection stations under Zhongyuan Ruide, which is expected to significantly enhance the company’s plasma resources, expand its plasma collection and production scale, and strengthen its overall competitiveness in the blood products industry.
This strategic acquisition aligns with Tiantan Biological’s growth strategy to consolidate its position in the blood products sector by leveraging existing operations and expanding into new markets. The deal underscores the company’s commitment to meeting the increasing demand for blood products and enhancing its product portfolio to serve patient needs more effectively. -Fineline Info & Tech
